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Aneurysmal subarachnoid hemorrhage (SAH) has an inci-dence of 6 to 7 per 100 000 person-years in most popula-
tions and accounts for 5% of all strokes. Half of the patients 
are younger than 55 years, and poor outcome exceeds 50%.1 
The most important cause of poor outcome in patients who 
survive the first 24 hours is delayed cerebral ischemia (DCI), 
which develops predominantly 4 to 10 days after SAH in 
≈30% of survivors.2 To date, the L-type calcium channel an-
tagonist nimodipine has been the only intervention proven to 
be effective in preventing DCI after SAH.3
Several factors, such as angiographic vasospasm, micro-
circulatory constriction, microthrombosis, cortical spreading 
depression, and delayed cell apoptosis, are postulated to be 
associated with the occurrence of DCI. Loss of or abnormal 
autoregulation by conducting microvasculature, variations in 
collateral and anastomotic blood flow, and metabolic and (epi)
genetic variations determine if angiographic vasospasm leads 
to tissue hypoxia and thus DCI. The final common pathway 
of the cause leading to DCI is a decrease in cerebral blood 
flow (CBF). Clinical signs of DCI may occur when the CBF 
and thus the delivery of oxygen no longer meets the demand 
of the brain tissue in the setting of impaired cerebrovascular 
autoregulation.4
After clinical signs of DCI occur, induced hyperten-
sion is a plausible but unproven therapeutic intervention.5,6 
The primary rationale for the use of induced hypertension 
is that raising perfusion pressure may increase CBF in high-
resistance vascular beds, increase collateral flow to ischemic 
brain regions, or both and, therefore, elevate brain tissue ox-
ygenation.5 However, its presumed effectiveness is based on 
uncontrolled case-series only.7 Furthermore, findings from our 
randomized controlled trial (RCT) did not support the use of 
induced hypertension to augment overall CBF in SAH patients 
with clinical signs of DCI.8 However, a small effect cannot be 
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definitively excluded because a trend was seen in improved 
CBF in areas with lowest perfusion. This might be of clinical 
interest, as hypoperfused areas might progress to infarction if 
not treated. Induced hypertension might thus be beneficial in 
improving CBF in regions with impaired perfusion.
In the participating centers of the current study, there is 
clinical equipoise if therapeutic hypertension induction is ben-
eficial. There is a state of honest, professional disagreement 
in the community of expert practitioners as to the preferred 
treatment (hypertension induction or not). As a consequence, 
some centers use hypertension induction when clinical signs 
of DCI occur while others do not, and even within centers, 
there is clinical equipoise between physicians. This provides 
the opportunity to study the effect of hypertension induction.
The objective of this study was to determine if induced 
hypertension could prevent DCI related cerebral infarcts and 
subsequent poor outcome when used after clinical signs of 




The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Study Design and Population
In this retrospective observational study, we included adult patients 
with aneurysmal SAH admitted to the Intensive Care Unit of the 
Academic Medical Center Amsterdam, University Medical Center 
Groningen, or University Medical Center Utrecht in the period be-
tween 2006 and 2015. Ethical approval was obtained from the Medical 
ethics committee from the University Medical Center Groningen, and 
the need for patient consent was waived (METc 2014/154). Patients 
with SAH were identified by disease codes as registered in the Dutch 
National Intensive Care Evaluation. Retrieval of subjects was cross-
checked with the intensive care unit patient data management system. 
In the National Intensive Care Evaluation registry database, patient 
characteristics, presence of chronic disease and comorbidity, reason 
for admission, disease, intensive care unit course, and outcome char-
acteristics are prospectively collected.9
Inclusion criteria were: (1) age 18 years or older; (2) subarach-
noid blood on CT scan; and (3) a ruptured intracranial aneurysm as 
the presumed cause of spontaneous SAH, preferably demonstrated 
by digital subtraction angiography or CT angiography. Patients with 
nonaneurysmal, for example, perimesencephalic or traumatic SAH 
were excluded.
All patients were kept under close observation with continuous 
monitoring of blood pressure, heart rate, ECG, and arterial oxygen 
saturation. They were treated according to a standardized protocol 
that consisted of strict bed rest until aneurysm occlusion, adminis-
tration of oral nimodipine, cessation of antihypertensive medica-
tion, and intravenous administration of fluid aimed at maintaining 
normovolemia.
Aneurysm occlusion was performed as soon as possible but was 
postponed in case of a poor clinical condition.
Practice differed between centers and in time, but in general, clin-
ical signs of DCI were treated with intravenous fluid aiming to restore 
possible hypovolemia. If blood pressure augmentation was initialized, 
norepinephrine was the vasopressor of choice in all 3 hospitals. The 
target was usually set at 20 mm Hg above the baseline mean or systolic 
blood pressure and then increased stepwise in a goal-directed fashion 
and titrated to clinical response, to a maximum systolic blood pressure 
of 220 mm Hg. Hypertension induction was tapered in patients not 
showing any clinical response after 24 hours at this maximum blood 
pressure but continued for 3 days in case any clinical improvement 
occurred. There were several reasons for not using hypertension in-
duction as a strategy to prevent cerebral infarction. Some centers use 
hypertension induction when clinical signs of DCI occur, whereas oth-
ers do not, but this changed over time even within centers.
Data Collection and Outcomes
Because this study only involved the anonymized retrospective evalu-
ation of clinical parameters and imaging acquired during routine clin-
ical care, informed consent was waived by the institutional Medical 
Ethics Committees of all 3 hospitals.
Data were extracted from the electronic medical files, such as 
clinical condition at admission, clinical signs of DCI, and treat-
ment of the aneurysm. Detailed disease-related information, such as 
amount of blood on the first CT scan, acute hydrocephalus, location 
of the aneurysm responsible for SAH, and recurrent bleeding, was 
assessed by studying all available brain imaging.
Clinical condition on admission at the tertiary center was assessed 
with the World Federation of Neurological Surgeons grading scale.10 
Poor neurological condition was defined as a World Federation of 
Neurological Surgeons IV or V.
The amount of subarachnoid blood at the admission CT scan 
was assessed using Hijdra sum scores, ranging from 0 to 30 for 
cisternal amount of blood and from 0 to 12 for ventricular amount 
of blood.11
We quantified the size of the frontal horns of the lateral ven-
tricles by means of the bicaudate index on all CT scans made within 
72 hours after SAH. To calculate age-adjusted relative sizes, the 
bicaudate indexes were divided by the corresponding upper limit 
per age group (95th percentile for age). Hydrocephalus was defined 
as an age-adjusted relative bicaudate index above 1.12 Acute hydro-
cephalus was considered present if any of the CT scans performed 
within the first 72 hours after the hemorrhage met this CT-defined 
criterion.
Recurrent bleeding was defined as an episode of sudden clinical 
deterioration with evidence of fresh blood on CT scan in comparison 
with a previous scan. If no CT scan was performed after a highly sug-
gestive clinical history, for example, fresh blood from a liquor drain, 
this was also scored as recurrent bleeding.
Clinical DCI was defined as a decrease of at least 1 point on the 
Glasgow Coma Scale sumscore or development of new focal neu-
rological deficits lasting at least 1 hour, or both, with exclusion of 
any other cause for neurological deterioration (eg, increasing hydro-
cephalus, recurrent bleeding, clinical signs of epilepsy, presence of 
an infectious disease, hypoglycemia (serum glucose <3.0 mmol/L), 
hyponatremia (serum sodium <125 mmol/L), or metabolic enceph-
alopathy because of renal or hepatic failure). The time of onset of 
clinical signs of DCI and the time of onset of hypertension induction 
were extracted from the medical files.
The primary outcome was a DCI related cerebral infarct that 
occurred >1 day after clinical signs of DCI, defined as the presence of 
a new hypodensity on CT-cerebrum within 30 days after admission, 
without any other explanation than DCI.13 The reason to include only 
patients without ischemic lesions on brain CT within 1 day after clin-
ical signs of DCI occurred was that it is unlikely that these very early 
infarctions could be prevented by induced hypertension.
The secondary outcome was poor functional outcome after 3 
months, defined as a modified Rankin score of 4, 5, or dead. The 
Rankin score was assessed by trained research nurses using a struc-
tured telephonic interview or during the patient’s visit at the outpa-
tient department when it was around 3 months after the SAH.
Statistical Analysis
Patient baseline characteristics are presented as means with SD for 
continuous, normally distributed variables, and medians with inter-
quartile range for continuous skewed parameters or frequencies (%) 
for categorical variables. Differences in baseline characteristics be-
tween patients with and without DCI related cerebral infarcts were 
assessed using the independent sample t test (for normally distributed 
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The relation between induced hypertension and the occurrence 
of DCI related cerebral infarcts on brain CT in patients with clin-
ical signs of DCI was assessed using a Cox regression model, which 
yields a hazard ratio (HR) with corresponding 95% CI.
To test the relation between induced hypertension for treatment 
of clinical signs of DCI and poor outcome at 3 months, logistic re-
gression was used, which yields an odds ratio with corresponding 
95% CI. In both the Cox regression as the logistic regression model 
outcomes were adjusted for treatment center and all baseline and di-
sease characteristics shown in Table 1.
To assess if patient characteristics are able to predict preven-
tion of cerebral infarction in patients with hypertension induction 
after clinical signs of DCI, we performed a stepwise regression 
analysis using a P value of 0.20 to eliminate variables with the 
backward method. The full model consists of patient and baseline 
characteristics mentioned in Table 1 with the exception of treat-
ment center in patients treated with hypertension induction.
Results
Between 2006 and 2015, 2561 SAH patients were admitted in 
the 3 participating hospitals. In 1722 patients, data were avail-
able for the occurrence of clinical signs of DCI and DCI re-
lated infarct. In 27 patients, it was unknown whether induced 
hypertension was applied, and in another 48 patients, hyper-
tension induction was used without clinical signs of DCI leav-
ing 1647 patients eligible for statistical analyses (Figure 1). 
Table 1. Baseline and Disease Characteristics of the Complete Cohort (n=1647) and Patients With Clinical Signs of DCI and No Concomitant Cerebral Infarct (n=300) 
and the Relation Between These Characteristics and the Occurrence of a DCI Related Cerebral Infarct
 
All Patients 
Patients With Clinical Signs of DCI
P Value
Patients With 
Clinical Signs of DCI
No Development of DCI 
Related Cerebral Infarct
Development of DCI 
Related Cerebral Infarct
n=1647 n=300 n=226 n=74
Mean age (SD) 56 (13) 56 (12) 56 56 0.88
Female sex 1131 (70%) 221 (74%) 168 (74%) 53 (71%) 0.65
Poor clinical condition at admission (WFNS 4–5) 719 (45%) 128 (43%) 97 (43%) 31 (42%) 0.88
Amount of blood on first CT scan (IQR)
  Median cisternal blood 23 (13–29) 25 (17–29) 21 24 0.006
  Median ventricular blood 2 (0–6) 2 (0–5) 3 4 0.097
Acute hydrocephalus 635 (42%) 115 (42%) 79 (35%) 36 (49%) 0.11
Location aneurysm
  Anterior circulation 1267 (77%) 261 (87%)
  Posterior circulation 243 (15%) 33 (11%) 20 (9%) 13 (18%) 0.005
  No aneurysm found 50 (3%) 6 (2%)    
  Unknown 87 (5%) …    
Treatment type
  Endovascular 722 (44%) 175 (59%) 128 (57%) 47 (64%) …
  Clip 539 (33%) 115 (39%) 94 (42%) 21 (28%) 0.09
  None 313 (19%) 4 (1%) 2 (<1%) 2 (2%) 0.31
  No aneurysm found 50 (3%) 6 (2%) 2 (<1%) 4 (5%) 0.03
  Unknown 23 (1%) …    
Recurrent bleeding
  Total 303 (18%) 36* (12%) 24 (11%) 12 (16%) 0.58
  CT proven 248 (15%) 27 (9%)    
  Clinically 55 (3%) 9 (3%)    
Clinical signs of DCI 479 (29%) 300    
Median day clinical signs of DCI (IQR) 6 (3–9) 6 (3–9)    
DCI related cerebral infarction 272 (17%) 74 (25%)    
Median day DCI related cerebral infarction (IQR) 7 (4–11) 4 (2–7)    
Hypertension induction 269 (56%)† 201 (67%)    
CT indicates computed tomography; DCI, delayed cerebral ischemia; IQR, interquartile range; SD, standard deviation; and WFNS, World Federation of Neurological 
Surgeons.
*Four patients had recurrent bleeding during induced hypertension.
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Patients were equally distributed between the 3 participating 
hospitals (range, 31%–36%).
Baseline and disease characteristics of these patients are 
shown in Table 1. Clinical signs of DCI occurred in 479 (29%) 
patients of whom 272 (57%) eventually developed a DCI re-
lated cerebral infarct. However, in 179 patients, cerebral is-
chemia was already present at brain CT at the time clinical 
signs of DCI were detected, and these patients were excluded 
for the primary analyses. Baseline and disease characteristics 
of the remaining 300 patients and the relation with the occur-
rence of a cerebral infarct after clinical signs of DCI is also 
shown in Table 1. Patients who developed a DCI related cere-
bral infarct after clinical signs of DCI harbored more frequent 
an aneurysm in the posterior cerebral circulation and had a 
larger amount of subarachnoid blood.
In 201 (67%) of the 300 patients, hypertension was in-
duced, and in the remaining 99 (33%) patients, hypertension 
was not induced. Of the 201 patients treated with induced hy-
pertension, 41 (20%) developed a DCI related cerebral infarct 
≥1 day after clinical signs of DCI occurred compared with 33 
(33%) with no induced hypertension (Table 2). With induced 
hypertension, the crude HR for DCI related cerebral infarction 
was 0.54; 95% CI, 0.34 to 0.86 and after adjustment, 0.59; 
95% CI, 0.35 to 0.99 (Table 3).
To illustrate the DCI related cerebral infarct free interval 
after clinical signs of DCI with or without induced hyperten-
sion survival curves are shown in Figure 2.
In patients who developed a DCI related cerebral infarct 
after clinical signs of DCI 48 (74%) had a poor outcome com-
pared with 64 (36%) in patients in whom clinical signs did not 
Figure 1. Flowchart of included patients. CT 
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lead to cerebral infarction (P<0.001; Table 4). With induced 
hypertension, the adjusted odds ratio for poor outcome was 
0.27; 95% CI, 0.14 to 0.55 (Table 3).
With the stepwise backward regression analyses, we found 
that only the amount of subarachnoidal blood independently 
predicts the prevention of a DCI related cerebral infarct (HR, 
0.95; 95% CI, 0.90–0.99) in patients treated with hyperten-
sion induction. Female sex (HR, 0.59; 95% CI, 0.27–1.29) 
and posterior location of the aneurysm (HR, 0.47; 95% CI, 
0.20–1.08) were the last remaining nonstatistically significant 
variables in the model.
Discussion
The findings of our study suggest that hypertension induction 
has a role in preventing DCI related cerebral infarcts after 
clinical signs of DCI have occurred. Preventing cerebral in-
farction by means of induced hypertension may also reduce 
poor outcome. Patients who developed DCI related cerebral 
infarcts had larger amount of subarachnoid blood and more 
frequent a posterior location of the aneurysm. The regression 
analysis confirmed a role for the amount of subarachnoidal 
blood to predict DCI related infarction in patients treated 
with induced hypertension. Patients with more subarachnoid 
blood have less chance for prevention of cerebral infarction 
with induced hypertension. Although the amount of subarach-
noid blood is a well-known risk factor for DCI, our study was 
not designed to prove an association with the development of 
a DCI related cerebral infarct after clinical signs of DCI has 
occurred. We did not cross-validate our stepwise regression 
model by splitting the data. Validation of the model should 
be performed in another, preferably prospective, dataset. The 
underlying pathogenesis and the possible effect of female sex 
and aneurysm location for development of DCI related cere-
bral infarcts should also be subject of further studies.
Despite its widespread application, there is no evidence 
that induced hypertension improves outcome in patients 
with DCI. The only RCT thus far did not add any evi-
dence to support induced hypertension.14 No observational 
study of this scale has been performed to support its ben-
eficial effect. Several observational studies exist, but none 
had a control or comparison group, and the largest study 
numbered 95 patients.15–28 Most studies focused on clin-
ical response to the intervention, whereas information on 
long-term functional outcome is scarce. Improvement of 
neurological deficits ranged from 50% to 100%, with most 
studies reporting improvement in around 80% of patients. 
None of the studies provided information on preventing 
DCI related cerebral infarcts.
Induced hypertension is hardwired in clinical practice 
and in international guidelines, but its impact on outcome 
has not yet been submitted to the scrutiny of an RCT. This 
was the aim of our multicenter RCT that was terminated 
prematurely because of slow recruitment that reduced power 
for the primary end point clinical outcome after 3 months.14 
The results from that study did not add any evidence to sup-
port induced hypertension and show that this treatment can 
lead to serious adverse events. Furthermore, there was no 
difference in global CBF between patients treated with hy-
pertension induction or not.8 The conduction of a large clin-
ical trial with sufficient power seems challenging given the 
lack of clinical equipoise in the international community. 
Further research should focus on better selection of patients 
that might benefit from hypertension induction. Selection 
of eligible patients might be accomplished with use of mul-
timodality monitoring, for example, transcranial Doppler, 
EEG, or near-infrared spectroscopy, that may detect DCI 
before clinical signs occur and, therefore, might improve 
the effect of this therapy as in many cases a cerebral infarct 
was already present at that time.
There are several limitations to this study; the most obvious 
being the retrospective nature of this study, which prevents us 
from making definitive conclusions. The major limitation of 
our study is that the reason for the treating physician to use 
hypertension induction or not is unknown. It seems likely that 
certain physicians always use hypertension induction, whereas 
others are more reluctant and that this difference is largely 
Table 2. Occurrence Cerebral Infarct With or Without Induced Hypertension After Onset of Clinical Symptoms of DCI 
Without Concomitant Infarct (n=300)
 
Hypertension Induction
P ValueNo (99) Yes (201)
DCI related cerebral infarct No (226) 66 160  
 Yes (74) 33 (33%) 41 (20%) 0.015
DCI indicates delayed cerebral ischemia.
Table 3. Occurrence of Cerebral Infarct and Poor Outcome Related to Hypertension Induction in Patients With Clinical Symptoms of DCI 
Without Concomitant Infarct (n=300)
 
 
Occurrence of Cerebral Infarct Poor Outcome*
Crude HR  
(95% CI)
Adjusted HR†  
(95% CI)
Crude OR  
(95% CI)
Adjusted OR†  
(95% CI)
Hypertension induction 0.54 (0.34–0.86) 0.59 (0.35–0.99) 0.39 (0.23–0.66) 0.27 (0.14–0.55)
DCI indicates delayed cerebral ischemia; and OR, odds ratio.
*Analysis includes 244 patients; of 56 patients outcome at 3 mo is missing.
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based on treatment center policy. For that reason, we included 
treatment center in our adjusted analyses. A reason not to use 
hypertension induction may be that the patient already has an 
elevated blood pressure which makes further augmentation 
futile. Another reason might be a poor clinical condition of 
the patient that could have led to withholding intensive treat-
ment like hypertension induction resulting in a self-fulfilling 
prophecy. Although poor clinical condition at admission did 
not differ between the treatment groups and adjustment for 
clinical condition at admission was performed, the clinical 
situation at the moment of initiating hypertension induction 
was not known. Finally, brain CT was not routinely performed 
leading to exclusion of patients for which it was uncertain if 
the primary end point, cerebral infarction, was reached. Also, 
patients with an early follow-up CT scan without cerebral is-
chemia might have developed a DCI related cerebral infarct 
thereafter. However, all patients with endovascular aneurysm 
repair had routine follow-up imaging, and the vast majority of 
the remaining patients had multiple and long-term follow-up 
brain imaging.
There were some slight differences in treatment protocols 
for induced hypertension between the 3 participating hospi-
tals, but the aim of this study was to test if hypertension in-
duction was able to prevent cerebral infarction irrespective 
of nuances in approach. Moreover, adjustment for treatment 
center did not change the results. Although adjustment for 
9 baseline characteristics (including treatment center) may 
cause an unstable multivariable model for the primary end-
point DCI related cerebral infarction, reducing it to the most 
relevant confounders did not change the results either.
Our RCT showed that induced hypertension can lead to 
serious adverse events.14 Because of the retrospective design, 
data on side effects were not available, which is a shortcoming 
of the current study. In theory, it could, therefore, be possible 
that patients with poor outcome, despite induced hyperten-
sion as treatment for DCI are those patients with severe side 
effects. However, the results of our study suggest that the ben-
efit of induced hypertension might overweigh the effect of 
complications.
Conclusions
Because of the retrospective and observational design of the 
study, no clear statements can be made, but the results suggest 
that hypertension induction seems an effective strategy to pre-
vent DCI related cerebral infarcts after clinical signs of DCI 




Figure 2. Cerebral infarct free interval after clin-
ical signs of delayed cerebral ischemia (DCI) 
occur dependent on hypertension induction 
(n=300). Straight line shows hypertension in-
duction, and dotted line shows no hypertension 
induction.
Table 4. Poor Outcome After Clinical Symptoms of DCI With or Without Development of Cerebral Infarct ≥1 Day After Clinical Symptoms Occur (n=244)*
  Poor Outcome P Value
  No (132) Yes (112)  
DCI related cerebral infarct No (179) 115 64 (36%)  
 Yes (65) 17 48 (74%) <0.001
DCI indicates delayed cerebral ischemia.
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